
Search Clinical Trials
The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care
Sponsor Condition of Interest |
---|
Perceptual Predictors of Visual Hallucinations in Parkinson's Disease
Boston University Charles River Campus
Parkinson's Disease
Visual Hallucination
Visual hallucinations (VH) are among the most distressing of the non-motor symptoms of
Parkinson's disease (PD). The investigators plan to examine the relation of perceptual
variables-basic vision, unusual perceptual experiences-to relevant functional variables such
as cognition,... expand
Visual hallucinations (VH) are among the most distressing of the non-motor symptoms of Parkinson's disease (PD). The investigators plan to examine the relation of perceptual variables-basic vision, unusual perceptual experiences-to relevant functional variables such as cognition, mood, and alertness/sleepiness in an online sample of persons with Parkinson's disease (PwPD). It is hypothesized that unusual perceptual experiences will relate significantly to the selected variables. This is an observational study only, and not an interventional study. Type: Observational Start Date: Aug 2022 |
Prenatal Breastfeeding Education
Boston Medical Center
Breast Feeding
In this pilot randomized control trial, the investigators will evaluate the feasibility and
acceptability of using a video and website in a prenatal visit to provide breastfeeding
education, focusing on how to hand express (HE) breast milk. Participants will be randomized... expand
In this pilot randomized control trial, the investigators will evaluate the feasibility and acceptability of using a video and website in a prenatal visit to provide breastfeeding education, focusing on how to hand express (HE) breast milk. Participants will be randomized to the video/website intervention group or to the control standard of care group. After delivery, participants will be asked to provide information on how long they breastfed and if they used the information in the video and website. Differences in the outcome measures will be analyzed between the two groups. Type: Interventional Start Date: Jun 2021 |
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
Boston Medical Center
End Stage Renal Disease
Hemodialysis represents a life line of patients with end stage renal disease, who are
commonly maintained on hemodialysis through catheters. Prolonged exposure to these catheters
eventually damages the walls of veins, which results in stenosis at the local site. This
condition... expand
Hemodialysis represents a life line of patients with end stage renal disease, who are commonly maintained on hemodialysis through catheters. Prolonged exposure to these catheters eventually damages the walls of veins, which results in stenosis at the local site. This condition is called central venous stenosis (CVS) and affects number of patients on hemodialysis in the United States and can compromise the dialysis efficacy. The current diagnostic modality for CVS is venography, which has several limitations. This study proposes to examine intravenous ultrasound (IVUS) as a potentially superior modality, which will provide additional information. Type: Interventional Start Date: Aug 2021 |
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Gladwin, Mark, MD
Sickle Cell Disease
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel
two-arm study aimed to determine if automated exchange blood transfusion and standard of care
administered to high mortality risk adult SCD patients reduces the total number of episodes... expand
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care. Type: Interventional Start Date: Feb 2020 |
Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
Alcohol Misuse
Primary: The primary objective of the study is to compare the efficacy of intranasal oxytocin
in reducing the weekly percentage of heavy drinking days over the 10 weeks of maintenance
treatment among subjects with moderate to severe Alcohol Use Disorder (AUD). A "heavy
drinking... expand
Primary: The primary objective of the study is to compare the efficacy of intranasal oxytocin in reducing the weekly percentage of heavy drinking days over the 10 weeks of maintenance treatment among subjects with moderate to severe Alcohol Use Disorder (AUD). A "heavy drinking day" is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men. Secondary: Secondary objectives include assessment of other measures of the effects of oxytocin compared with placebo on reduction of alcohol use as well as effects on psychological assessments, alcohol craving, alcohol-related consequences, cigarette smoking and other nicotine use, retention in the study, safety, and application site (nares) tolerability throughout the study. Type: Interventional Start Date: May 2022 |
MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study
Boston Medical Center
Opioid-use Disorder
Neonatal Abstinence Syndrome
Pregnancy, High Risk
Alcohol Use Disorder
This is a multi-center prospective comparative cohort study examining the safety, efficacy,
pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use
disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery
will... expand
This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone. Type: Observational Start Date: Dec 2018 |
Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
Boston University
Opioid-Related Disorders
Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain,
depression, opioid and other substance misuse, and functioning. It has a structured agenda,
uses behavioral activation, involves explicit and ongoing psychoeducation, and includes a
behavioral... expand
Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain, depression, opioid and other substance misuse, and functioning. It has a structured agenda, uses behavioral activation, involves explicit and ongoing psychoeducation, and includes a behavioral health specialist (BHS) trained extensively in the nature of pain and opioid misuse, including how to assess for red flags of opioid relapse. Devised specifically for primary care patients receiving buprenorphine, TOPPS is collaborative (PCP, BHS, and patient) and focuses on pain and physical symptoms in order to decrease the need to turn to substance misuse to avoid pain, and to foster patient's abilities to achieve their long-term life goals. In this study, TOPPS is compared to a health education contact-control condition among 250 persons with opioid use disorder recruited from two primary care based buprenorphine programs. The investigators will provide both interventions over 3 months, and follow the patients for a total of 12 months in order to observe both short-term and longer-term effects of TOPPS. Type: Interventional Start Date: Aug 2019 |
Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite
Harvard School of Public Health (HSPH)
HIV/AIDS
This is a prospective cohort study designed to define the impact of HIV infection and
antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition
to adulthood.
expand
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition to adulthood. Type: Observational Start Date: Nov 2017 |
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
Boston University
Atopic Dermatitis
This single blind study is to primarily evaluate wearable devices and Observer Reported Itch
Assessment in children to assess reduction of itch and night-time scratch in response to
Crisaborole treatment vs. vehicle treatment (active control comparator without crisaborole)... expand
This single blind study is to primarily evaluate wearable devices and Observer Reported Itch Assessment in children to assess reduction of itch and night-time scratch in response to Crisaborole treatment vs. vehicle treatment (active control comparator without crisaborole) in children with atopic dermatitis (AD). Participants, age 3 months to 5 years with symptomatic mild to moderate AD, along with their primary caregivers will be recruited. The goal of this study is to more fully evaluate the rapid onset of night-time itch and scratch relief, as well as improvements in sleep following treatment with Crisaborole in comparison to vehicle treatment in children with AD. the study will also assess the quality of life (QoL) and sleep within the associated caregivers. Type: Interventional Start Date: Jul 2022 |
Serum-Protein-Based Indices for the Progression of Fracture Healing and Nonunion
Major Extremity Trauma Research Consortium
Humerus Fractures
To define a serum protein-based diagnostic for the progression and failure of fracture
healing, through the identification of a set of serum proteins that appear at early times of
biological healing and show a specific correlation with later radiological and functional
signs... expand
To define a serum protein-based diagnostic for the progression and failure of fracture healing, through the identification of a set of serum proteins that appear at early times of biological healing and show a specific correlation with later radiological and functional signs used to define delayed healing and non-union. Type: Observational Start Date: Jun 2021 |
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
Boston University
Rural Health
Pulmonary Disease
Heart Diseases
The Boston University Medical Campus (BUMC) will serve as the site for the RURAL Study
Coordinating Center, led by PI Vasan Ramachandran, MD, and the Pulmonary Core, led by George
O'Connor, MD.
The primary function of the Study Coordinating Center (SCC) is to serve as an... expand
The Boston University Medical Campus (BUMC) will serve as the site for the RURAL Study Coordinating Center, led by PI Vasan Ramachandran, MD, and the Pulmonary Core, led by George O'Connor, MD. The primary function of the Study Coordinating Center (SCC) is to serve as an administrative liaison between all of the RURAL study's cores. The SCC schedules, facilitates, and hosts, all RURAL meetings including preparation for Observational Study Monitoring Board (OSMB) meetings, and maintains direct communication with the study's program officers at NHLBI. The SCC monitors the overall progress of RURAL and keeps all RURAL cores abreast of study updates through meetings, emails, newsletters. It also maintains the official RURAL website and serves as an administrator for investigators seeking to collaborate with RURAL through the submission of Ancillary Studies. The SCC will have no direct interaction with any participants, nor will it have access to identifiable data. The RURAL pulmonary core's primary function will be to read the daily Pulmonary Function Tests (PFTs) performed by participants at each of RURAL's recruiting sites (Alabama, Kentucky, Louisiana, Mississippi). The BUMC Pulmonary Core investigators will receive de-identified data on a daily basis sent by the Statistical Data Coordinating Center at the University of Pennsylvania and will provide a clinical interpretation for each test and "score" the results for quality assurance purposes. Although the Pulmonary Core investigators will not have direct interaction with any participants, in rare circumstances, there may be a need to review identifiable results in the case of a medical emergency at one of the recruiting sites. The pulmonary core will also provide training for all staff who will carry out PFTs. Type: Observational Start Date: Jan 2021 |
Implementing a Skills Training Evidence-Based Treatment for Posttraumatic Stress Disorder in Primary...
Boston Medical Center
Posttraumatic Stress Disorder
A majority of residents in low income communities have been exposed to a potentially
traumatic event, and up to half (30-50%) of trauma-exposed residents in safety net clinical
settings meet criteria for posttraumatic stress disorder (PTSD). Despite this, only 13%
receive... expand
A majority of residents in low income communities have been exposed to a potentially traumatic event, and up to half (30-50%) of trauma-exposed residents in safety net clinical settings meet criteria for posttraumatic stress disorder (PTSD). Despite this, only 13% receive treatment. Poor access to PTSD treatment is due to a shortage of mental health specialists. This study aims to evaluate the implementation and effectiveness of a brief, cognitive-behavioral intervention for posttraumatic stress disorder (PTSD)-Skills Training in Affective and Interpersonal Regulation (STAIR)- that will be offered in Boston Medical Center (BMC)'s primary care clinics as the new standard of care following integrated behavioral healthcare (IBH) therapist training. In response to clinician capacity concerns and the impact of the COVID-19 pandemic, we will be offering the intervention in both clinician-administered and self-paced, web-administered formats. The evidence base suggests that STAIR, delivered both synchronously (in-person/telehealth STAIR) and asynchronously (webSTAIR), is associated with significant improvements in PTSD and depression symptoms. Type: Interventional Start Date: Jun 2021 |
Second eFramngham Heart Study
Boston University
Cardiovascular Diseases
In the electronic Framingham Heart Study (eFHS), the investigators developed and deployed a
mobile app to collect cardiovascular risk factors and event data and test them against
cardiovascular data collected in the Framingham research clinic for the FHS.
Participants enrolled... expand
In the electronic Framingham Heart Study (eFHS), the investigators developed and deployed a mobile app to collect cardiovascular risk factors and event data and test them against cardiovascular data collected in the Framingham research clinic for the FHS. Participants enrolled in eFHS receive a series of digital surveys modules to complete on a regularly occurring schedule. The objective of the planned randomized trial is to test the effect of administering half of survey modules every 2 weeks versus all survey modules every 4 weeks on improving participants' response rates. There will be 4 survey periods. Period 1 encompasses all survey modules administered from baseline up to week 8 (19 surveys/tasks per participant); period 2 from week 8 up to week 16 (18 surveys/tasks per participant); period 3 from week 16 up to week 24; period 4 from week 24 (16 surveys/tasks per participant). Type: Interventional Start Date: Jun 2021 |
Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs
Sera Prognostics, Inc.
Preterm Labor
Preterm Birth
This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm
birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the
incidence of adverse pregnancy outcomes.
expand
This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes. Type: Interventional Start Date: Nov 2020 |
SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive...
Southwest Oncology Group
Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Lung Small Cell Carcinoma
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic
cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in
treating patients with small cell lung cancer. MRI scans are used to monitor the possible
spread... expand
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans. Type: Interventional Start Date: Jan 2020 |
Group-based Mindfulness for Chronic Pain in the Primary Care Setting
Boston Medical Center
Chronic Pain
Back Pain
The purpose of this pragmatic clinical trial (PCT) research is to determine whether a
group-visit approach modeled on Mindfulness-Based Stress Reduction can improve function for
persons with chronic low back pain. This will be done by an embedded PCT within the
evidence-based... expand
The purpose of this pragmatic clinical trial (PCT) research is to determine whether a group-visit approach modeled on Mindfulness-Based Stress Reduction can improve function for persons with chronic low back pain. This will be done by an embedded PCT within the evidence-based "OPTIMUM" (Optimizing Pain Treatment In Medical settings Using Mindfulness) program. Type: Interventional Start Date: May 2021 |
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year...
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and
radiation therapy (chemoradiation) works in treating patients with stage III non-small cell
lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal
antibodies,... expand
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab. Type: Interventional Start Date: Apr 2020 |
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
RTOG Foundation, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
This phase II trial with a safety run-in component will evaluate whether the addition of
pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the
progression-free survival for patients with recurrent or new second primary Head and Neck
Squamous... expand
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC). Type: Interventional Start Date: Nov 2018 |
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous...
AIDS Malignancy Consortium
Anal Intraepithelial Neoplasia
High-grade Squamous Intraepithelial Lesion
HIV Infection
This randomized phase III trial studies imiquimod or fluorouracil to see how well they work
compared to observation in treating patients with high-grade anal squamous skin lesions who
are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may... expand
This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions. Type: Interventional Start Date: Dec 2015 |
Mastering the World of Work (MWW): RCT
Boston University Charles River Campus
Mental Disorders
Employment
Metacognition
Employment, Supported
The purpose of this study is to conduct a randomized clinical trial for an innovative
intervention entitled "Mastering the World of Work" (MWW). MWW aims to improve the employment
outcomes of individuals with psychiatric disabilities who experience metacognitive deficits.... expand
The purpose of this study is to conduct a randomized clinical trial for an innovative intervention entitled "Mastering the World of Work" (MWW). MWW aims to improve the employment outcomes of individuals with psychiatric disabilities who experience metacognitive deficits. Metacognitive deficits are represented in diminished capacity to form an integrated sense of self and others and respond to challenges in life. The randomized trial (N=60) will be conducted with recipients of Supported Employment (Individual Placement and Support) services at the Mental Health Center of Greater Manchester, in Manchester, NH. Given COVID-19 safety considerations, the MWW intervention will be delivered in a hybrid manner depending on the preferences of both clinicians and clients at the MHCGM at any given point of the study. The feasibility of remote delivery of the intervention has been established as part of a pilot study conducted at BU CPR. Thus, clinicians may deliver the intervention using HIPAA-complaint ZOOM connection and/or in person. The assessments will be administered at baseline, 6, 12, and 18 months post baseline remotely by BU staff using a HIPAA-complaint ZOOM connection. The RCT will establish preliminary evidence about the incremental effectiveness of the MWW intervention to improve the employment outcomes of individuals with metacognitive deficits who receive high fidelity IPS services. Study participants randomized to the control condition will receive IPS services as usual. Type: Interventional Start Date: Jun 2022 |
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Boston University
Diabetes Mellitus, Type 2
Endothelial Dysfunction
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can
lead to a higher chance of developing heart attacks or strokes. New medications for T2DM
including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2)
inhibitor,... expand
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels. The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This study will provide novel information regarding the mechanism of effects of novel treatments for endothelial function and vascular health in patients with T2DM to reduce cardiovascular (CV) risk. The research aims to assess the: - effects of dapagliflozin on EC phenotype. - impact of dapagliflozin on vasodilator function and additional measures of vascular health including arterial stiffness and circulating markers of vascular health. Type: Interventional Start Date: May 2022 |
A Hybrid Effectiveness Implementation Study of Latino/a Alcohol and Drug Users
Boston University Charles River Campus
Alcohol Use Disorder
Drug Use
Psychological Distress
Alcohol use is a significant problem among Latinxs and immigration-related stress increases
risk for substance use. A theoretically-based cultural adaptation of motivational
interviewing (CAMI) that specifically integrated discussion of immigration-related stressors
(e.g.,... expand
Alcohol use is a significant problem among Latinxs and immigration-related stress increases risk for substance use. A theoretically-based cultural adaptation of motivational interviewing (CAMI) that specifically integrated discussion of immigration-related stressors (e.g., stigma, social isolation) resulted in significant reductions in alcohol-related harms for those Latinx heavy drinkers with high discrimination compared to standard MI, and reduced anxiety and depressive symptoms one year later compared to MI. Rigorous tests that examine theoretically-informed adaptation of efficacious addiction interventions are not common, yet are needed to advance implementation science. This Hybrid Type 1 Effectiveness-Implementation study will investigate the feasibility of implementing CAMI in a real-world clinical setting. The key questions are: Would CAMI have positive effects among individuals who use both drugs and alcohol? How do providers view this intervention? The investigators will collaborate with a primary care center that serves a mainly Latinx client population to train their Community Wellness Advocates (CWAs) to deliver CAMI to patients who are heavy drinkers. The investigators will conduct a concurrent investigation on the process of implementing CAMI in primary care - a two-arm randomized clinical effectiveness trial will enroll Latinx heavy drinkers (18 years or older) in primary care who use alcohol (and may use other drugs) - and follow them for 12 months after the intervention. Specific Aims are: (1) To examine the impact of CAMI plus a booster session (vs. assessment only) on outcomes: % heavy drinking days, frequency of alcohol-related consequences, depressive/anxiety symptoms, and number of illicit drug use days, using a Hybrid Type 1 Effectiveness-Implementation design and (2) To gather indicators of implementation outcome from multiple stakeholders using a mixed-methods approach. The investigators will follow Curran's framework to evaluate the process of implementation and Proctor's framework to measure implementation outcomes. This study, a first to examine the acceptability of culturally-adapted addiction treatments in primary care settings, will answer essential questions on implementing evidence-based care for Latinxs that can improve health disparities related to substance use. Long term goals are to translate the lessons from this Hybrid study to the broader community to focus on population health for all primary care patients. Type: Interventional Start Date: Mar 2022 |
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™
Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
Directly examine whether early (6-month) imaging with DaTscan and [¹⁸F] AV-133 will provide
an early signal of disease progression in recently diagnosed untreated PD patients.
expand
Directly examine whether early (6-month) imaging with DaTscan and [¹⁸F] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients. Type: Observational Start Date: Sep 2020 |
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage...
ECOG-ACRIN Cancer Research Group
Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
This phase II trial investigates how well biomarkers on PET/CT imaging drive early
discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be
removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for
patients... expand
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy. Type: Interventional Start Date: Aug 2020 |
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients...
Weill Medical College of Cornell University
Amyloid
AL Amyloidosis
Refractory AL Amyloidosis
This study will test the hypothesis that in patients with previous daratumumab exposure,
combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher
complete remission (CR) rates in relapsed/refractory amyloidosis than historical
pomalidomide/dexamethasone... expand
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment. Type: Interventional Start Date: Apr 2021 |
- Previous
- Next